Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center

Farkas Klaudia and Rutka Mariann and Ferenci Tamás and Nagy Ferenc and Bálint Anita and Bor Renáta and Milassin Ágnes and Fábián Anna and Szántó Kata and Végh Zsuzsanna and Kürti Zsuzsanna and Lakatos Péter László and Szepes Zoltán and Molnár Tamás: Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center.
EXPERT OPINION ON BIOLOGICAL THERAPY, 17 (11). pp. 1325-1332. ISSN 1471-2598 (2017)

[thumbnail of 3269325_Farkas_Exp.Opin.pdf]
Preview
Text
3269325_Farkas_Exp.Opin.pdf - Accepted Version

Download (2MB) | Preview
Item Type: Journal Article
Journal or Publication Title: EXPERT OPINION ON BIOLOGICAL THERAPY
Date: 2017
Volume: 17
Number: 11
Page Range: pp. 1325-1332
ISSN: 1471-2598
Faculty/Unit: Faculty of Medicine
Institution: Szegedi Tudományegyetem
Language: English
MTMT rekordazonosító: 3269325
DOI azonosító: https://doi.org/10.1080/14712598.2017.1363885
Date Deposited: 2017. Oct. 26. 10:56
Last Modified: 2020. Feb. 13. 10:20
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/12187
Web of Science® Times Cited: 17 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year